Abstract：
BACKGROUND: Molecular diagnosis in allergology helps to identify multiple allergenic molecules simultaneously. The use of purified and/or recombinant allergens increases the accuracy of individual sensitization profiles in allergic patients.
OBJECTIVE: To assess the impact of molecular diagnosis through the ImmunoCAPTM ISAC 112 microarray on etiological diagnosis and specific immunotherapy (SIT) prescription. This was compared to the use of conventional diagnoses in pediatric, adolescent, and young adult patients with rhinitis or rhinoconjunctivitis and/or allergic asthma, sensitized to three or more pollen allergens of different botanical species.
METHODS: A multicenter, prospective, observational study was conducted in patients aged 3-25 years who received care at the Allergology service of 14 hospitals in Catalonia from 2017 to 2020. Allergology diagnosis was established based on the patient\'s clinical assessment and the results of the skin prick test and specific immunoglobulin E assays. Subsequently, molecular diagnosis was conducted using ImmunoCAPTM ISAC® 112 to recombinant and/or purified allergen components.
RESULTS: A total of 109 patients were included; 35 (32.1%) were pediatric patients and 74 (67.9%) were adolescents or young adults (mean age: 18 years), with 58.0% being females. A change of 51.0% was observed in SIT prescription following molecular etiological diagnosis by means of a multi-parameter microarray.
CONCLUSIONS: Molecular diagnosis by means of multi-parameter tests increases the accuracy of etiological diagnosis and helps to define an accurate composition of SIT.
OBJECTIVE: To assess the impact of molecular diagnosis through the ImmunoCAPTM ISAC 112 microarray on etiological diagnosis and specific immunotherapy (SIT) prescription. This was compared to the use of conventional diagnoses in pediatric, adolescent, and young adult patients with rhinitis or rhinoconjunctivitis and/or allergic asthma, sensitized to three or more pollen allergens of different botanical species.
METHODS: A multicenter, prospective, observational study was conducted in patients aged 3-25 years who received care at the Allergology service of 14 hospitals in Catalonia from 2017 to 2020. Allergology diagnosis was established based on the patient\'s clinical assessment and the results of the skin prick test and specific immunoglobulin E assays. Subsequently, molecular diagnosis was conducted using ImmunoCAPTM ISAC® 112 to recombinant and/or purified allergen components.
RESULTS: A total of 109 patients were included; 35 (32.1%) were pediatric patients and 74 (67.9%) were adolescents or young adults (mean age: 18 years), with 58.0% being females. A change of 51.0% was observed in SIT prescription following molecular etiological diagnosis by means of a multi-parameter microarray.
CONCLUSIONS: Molecular diagnosis by means of multi-parameter tests increases the accuracy of etiological diagnosis and helps to define an accurate composition of SIT.
摘要：
背景：变态反应学中的分子诊断有助于同时鉴定多种变应原性分子。纯化和/或重组变应原的使用增加了过敏患者中个体致敏特性的准确性。
目的：通过ImmunoCAPTMISAC112芯片评估分子诊断对病因诊断和特异性免疫治疗（SIT）处方的影响。这与在儿科中使用常规诊断进行了比较，青春期,和年轻的成人患者有鼻炎或鼻结膜炎和/或过敏性哮喘，对不同植物物种的三种或更多种花粉过敏原敏感。
方法：多中心，prospective,我们对2017年至2020年在加泰罗尼亚14家医院的变态反应学服务机构接受治疗的3-25岁患者进行了观察性研究.根据患者的临床评估以及皮肤点刺试验和特异性免疫球蛋白E测定的结果，建立了变态反应学诊断。随后，使用ImmunoCAPTMISAC®112对重组和/或纯化的过敏原成分进行分子诊断。
结果：共纳入109例患者；35例（32.1％）为儿科患者，74例（67.9％）为青少年或年轻人（平均年龄：18岁），58.0%是女性。通过多参数微阵列进行分子病因诊断后，在SIT处方中观察到51.0％的变化。
结论：通过多参数测试的分子诊断提高了病因诊断的准确性，并有助于确定SIT的准确组成。
目的：通过ImmunoCAPTMISAC112芯片评估分子诊断对病因诊断和特异性免疫治疗（SIT）处方的影响。这与在儿科中使用常规诊断进行了比较，青春期,和年轻的成人患者有鼻炎或鼻结膜炎和/或过敏性哮喘，对不同植物物种的三种或更多种花粉过敏原敏感。
方法：多中心，prospective,我们对2017年至2020年在加泰罗尼亚14家医院的变态反应学服务机构接受治疗的3-25岁患者进行了观察性研究.根据患者的临床评估以及皮肤点刺试验和特异性免疫球蛋白E测定的结果，建立了变态反应学诊断。随后，使用ImmunoCAPTMISAC®112对重组和/或纯化的过敏原成分进行分子诊断。
结果：共纳入109例患者；35例（32.1％）为儿科患者，74例（67.9％）为青少年或年轻人（平均年龄：18岁），58.0%是女性。通过多参数微阵列进行分子病因诊断后，在SIT处方中观察到51.0％的变化。
结论：通过多参数测试的分子诊断提高了病因诊断的准确性，并有助于确定SIT的准确组成。
